<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cy--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15700038</article-id><article-id pub-id-type="pmc">2361887</article-id><article-id pub-id-type="pii">6602394</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6602394</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Valle</surname><given-names>J W</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Dangoor</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Beech</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sherlock</surname><given-names>D J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>S M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Scarffe</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Swindell</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ranson</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Christie Hospital NHS Trust, Manchester, Wilmslow Road, Manchester M20 4BX, UK</aff><aff id="aff2"><label>2</label>The Pennine Acute Hospitals NHS Trust, North Manchester General Hospital, Delaunays Road, Crumpsall, Manchester M8 5RB, UK</aff><aff id="aff3"><label>3</label>UCLH, The Middlesex Hospital, Mortimer Street, London W1T 3AA, UK</aff><aff id="aff4"><label>4</label>East and North Herts NHS Trust, Lister Hospital, Coreys Mill Lane, Stevenage, Herts SG1 4AB, UK</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:juan.valle@christie-tr.nwest.nhs.uk">juan.valle@christie-tr.nwest.nhs.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>02</month><year>2005</year></pub-date><pub-date pub-type="collection"><day>22</day><month>02</month><year>2005</year></pub-date><pub-date pub-type="ppub"><day>28</day><month>02</month><year>2005</year></pub-date><volume>92</volume><issue>4</issue><fpage>628</fpage><lpage>630</lpage><history><date date-type="received"><day>29</day><month>09</month><year>2004</year></date><date date-type="rev-recd"><day>07</day><month>12</month><year>2004</year></date><date date-type="accepted"><day>13</day><month>12</month><year>2004</year></date></history><copyright-statement>Copyright 2005, Cancer Research UK</copyright-statement><copyright-year>2005</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>Monthly intravenous pegylated liposomal doxorubicin (PLD) 50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0&#x00025;, stable disease 19&#x00025;, median time to progression of 2.4 months, 1-year survival of 25&#x00025; and median survival of 6.5 months.</p></abstract><kwd-group><kwd>pegylated liposomal doxorubicin</kwd><kwd>hepatocellular carcinoma</kwd><kwd>phase II</kwd></kwd-group></article-meta></front><body><p>Surgery, currently the only treatment offering long-term cure, is possible in a minority of patients with hepatocellular carcinoma (HCC) (<xref ref-type="other" rid="bib7">Llovet <italic>et al</italic>, 2003</xref>). In selected patients with unresectable, liver-only, disease hepatic embolisation or chemoembolisation confers a survival advantage compared with conservative management (<xref ref-type="other" rid="bib8">Llovet <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib9">Lo <italic>et al</italic>, 2002</xref>). However, in the recent meta-analysis, this effect may be limited to chemoembolisation but not embolisation (<xref ref-type="other" rid="bib6">Llovet and Bruix, 2003</xref>). Chemotherapy for inoperable and extrahepatic disease is relatively ineffective; the current &#x02018;standard', doxorubicin, has a response rate of 16&#x00025; (range 0&#x02013;35&#x00025;) in a review of eight trials including 475 evaluable patients (<xref ref-type="other" rid="bib2">Engstrom <italic>et al</italic>, 1993</xref>). It is associated with a small survival advantage over supportive care alone in a randomised study of 106 chemotherapy-na&#x000ef;ve patients at the expense of significant toxicity (mucositis, alopecia, myelosuppression and cardiotoxicity) (<xref ref-type="other" rid="bib5">Lai <italic>et al</italic>, 1988</xref>).</p><p>Liposomes, capable of encapsulating anticancer agents without chemical modulation, accumulate preferentially in the reticuloendothelial system (<xref ref-type="other" rid="bib18">Weinstein, 1984</xref>). This uptake may be evaded by &#x02018;stealth' liposomes (formed by altering the liposome lipid composition), which preferentially exit the circulation via leaky capillaries and are predicted to accumulate in tumours exhibiting extensive neo-vascularisation (such as HCC) leading to higher concentrations and enhanced antitumour activity (<xref ref-type="other" rid="bib19">Wu <italic>et al</italic>, 1993</xref>). Pegylated liposomal doxorubicin (PLD), an intravenous preparation of doxorubicin hydrochloride encapsulated in long-acting pegylated &#x02018;stealth' liposomes, can avoid rapid hepatic uptake resulting in a prolonged circulation time. Compared to conventional doxorubicin, intratumoural doxorubicin levels in tumour-bearing mice were substantially higher when using PLD. Moreover, enhanced cytotoxicity of an HCC cell line has been demonstrated using &#x02018;stealth' liposomes compared to conventional doxorubicin (<xref ref-type="other" rid="bib15">Shimizu <italic>et al</italic>, 1996</xref>).</p><p>Dose-limiting toxicities of PLD include reversible neutropaenia, stomatitis and plantar-palmar erythrodysaesthesia. Alopecia and emesis are infrequent (<xref ref-type="other" rid="bib17">Uziely <italic>et al</italic>, 1995</xref>). A phase I study in 33 patients with advanced HCC determined neutropaenia as the dose-limiting toxicity at 60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and recommended 50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> every 28 days as the phase II dosing regimen (Schering Plough &#x02013; data on file). Endomyocardial biopsies have shown PLD to have a superior cardiac safety profile compared to nonliposomal doxorubicin (<xref ref-type="other" rid="bib1">Berry <italic>et al</italic>, 1998</xref>).</p><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Patient selection</title><p>An open-label, phase II study was performed. Chemotherapy-na&#x000ef;ve patients (including chemotherapy as part of chemoembolisation procedures) with histologically proven HCC, aged &#x02a7e;18 years, with measurable disease by CT/MRI scan (WHO criteria), WHO performance score (PS) of &#x02a7d;2, life expectancy &#x02a7e;3 months, left ventricular ejection fraction (LVEF) &#x02a7e;50&#x00025; (by MUGA or echocardiography), haemoglobin &#x0003e;9&#x02009;g&#x02009;dl<sup>&#x02212;1</sup>, white blood cells &#x02a7e;3.0 &#x000d7; 10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>, neutrophils &#x02a7e;1.5 &#x000d7; 10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup> and platelets &#x02a7e;100&#x02009;000&#x02009;mm<sup>&#x02212;3</sup>, serum creatinine &#x0003c;1.5 &#x000d7; upper limit of normal (ULN), bilirubin &#x0003c;1.5 &#x000d7; ULN and AST/ALT &#x0003c;2 &#x000d7; ULN (unless related to primary disease when value &#x0003c;5 &#x000d7; ULN) were eligible. Patients with New York Heart Association&#x02a7e;Class II cardiac disease, patients who were pregnant, lactating or were unwilling to use contraception during the study were excluded. The appropriate Local Research Ethics Committees at each institution approved the study and all patients gave written informed consent prior to study entry.</p></sec><sec><title>Treatment</title><p>Patients received PLD (Caelyx&#x000ae;/Doxil&#x000ae;, Schering-Plough headquarters, Kenilworth, NJ, USA) 50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> in 250&#x02013;500&#x02009;ml of 5&#x00025; dextrose i.v. over 1&#x02009;h on day 1 of each 28-day cycle. Retreatment occurred upon recovery of platelets to &#x02a7e;75&#x02009;000&#x02009;mm<sup>&#x02212;3</sup>, ANC to &#x02a7e;1.5 &#x000d7; 10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup> and skin toxicity or stomatitis to grade &#x02a7d;1. A 25&#x00025; dose reduction was permitted for delayed recovery from toxicity or grade &#x02a7e;2 toxicity. Patients were withdrawn from the study for a deferral of a treatment cycle (for toxicity) by more than 2 weeks.</p></sec><sec><title>Evaluation</title><p>Tumour assessments (CT/MRI scan) and cardiac assessments (ECG/LVEF) were made at baseline and after cycles 3, 6 and 9. Patients received PLD until disease progression, unacceptable toxicity, patient choice or physician's discretion. Toxicity (NCI-Common Toxicity Criteria, version 2.0), vital signs and serum biochemistry (including serum AFP) were assessed at baseline and at every cycle with weekly blood counts during the study period. All patients were followed up for survival data.</p></sec></sec><sec><title>RESULTS</title><p>A total of 16 patients (see <xref rid="tbl1" ref-type="table">Table 1</xref> for patient characteristics) received a total of 47 cycles (median 3, range 1&#x02013;9) at two institutions (Christie Hospital, Manchester, UK (<italic>n</italic>=13) and University College Hospital, London, UK (<italic>n</italic>=3)) between November 1998 and April 2002.</p><sec><title>Toxicity</title><p>Treatment was well tolerated with most toxicities reported at grade 1. Grade 3&#x02013;4 toxicity included leucopaenia, neutropaenia, nausea/vomiting and lethargy in 12, 12, 6 and 6&#x00025; of patients, respectively (and 4, 6, 2 and 2&#x00025; of cycles, respectively). Dose delays were required on three occasions and a total of three dose reductions were made. One patient with persistent grade 4 neutropaenia was withdrawn from treatment. No cardiac toxicity was observed. Hepatic toxicity was mostly grade 1; grade 2 hyperbilirubinaemia was seen in 27&#x00025; of patients (9&#x00025; of cycles) and elevated serum alkaline phosphatase in 9&#x00025; of patients (3&#x00025; of cycles). No grade 2 transaminitis or grade 3&#x02013;4 hepatotoxicity was documented (<xref rid="tbl2" ref-type="table">Table 2</xref>
).</p></sec><sec><title>Response and survival</title><p>No responses were seen in the first 16 patients and the study was closed to accrual as the minimal threshold of activity had not been reached according to the Simon one sample, two-stage design (<xref ref-type="other" rid="bib16">Simon, 1989</xref>). Three patients (19&#x00025;) had stable disease after three cycles, with disease progression in the remaining patients (including the three patients with FLHCC). One of the three patients with stable disease had ongoing stable disease after six and nine cycles of treatment. The median time to disease progression in all patients was 2.4 months with 1-year and 2-year survival rates of 25 and 12.5&#x00025;, respectively. The median survival of all patients was 6.5 months. As expected, patients with FLHCC had a longer median survival (20.5 months) than patients with standard HCC histology (4.3 months).</p><p>Second-line chemotherapy was administered to six patients (38&#x00025;) (gemcitabine alone (<italic>n</italic>=3) or with cisplatin (<italic>n</italic>=3)). Two patients receiving cisplatin&#x02013;gemcitabine achieved disease stabilisation having previously progressed, the remainder had disease progression. One patient with FLHCC achieved a sustained partial response with continuous-infusion 5-FU and interferon having failed PLD followed by cisplatin&#x02013;gemcitabine and remains alive at 54 months.</p><p>Two patients (13&#x00025;) with disease confined to the liver were deemed suitable for chemoembolisation at first assessment. The choice was made to proceed with PLD in the first instance (prior chemoembolisation would have deemed them ineligible). Both progressed after three cycles of PLD and then underwent chemoembolisation (achieving survivals of 16 and 25 months, respectively). Five patients (31&#x00025;) received palliative hormone therapy.</p></sec></sec><sec><title>DISCUSSION</title><p>Doxorubicin, with modest activity, is a toxic agent and patients with advanced HCC are frequently unwell due to their underlying tumour and hepatic dysfunction. There was an expectation that its efficacy could be maintained (or even enhanced) with the better tolerated PLD formulation (<xref ref-type="other" rid="bib17">Uziely <italic>et al</italic>, 1995</xref>).</p><p>A number of studies contemporary to ours (see <xref rid="tbl3" ref-type="table">Table 3</xref>
) have shown, at best, response rates of 10&#x02013;17&#x00025; (<xref ref-type="other" rid="bib13">Ruff <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib14">Schmidinger <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib4">Hong and Tseng, 2003</xref>). Two studies, as in our case, revealed no responses: in the first, no objective responses were seen in 16 patients receiving 30&#x02013;40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> three-weekly. With a median survival of 20 weeks, the authors concluded that PLD was ineffective (<xref ref-type="other" rid="bib3">Halm <italic>et al</italic>, 2000</xref>). <xref ref-type="other" rid="bib10">Miller <italic>et al</italic> (2002)</xref> reached the same conclusion with a 0&#x00025; response rate in a mixed study of 10 HCC (and eight cholangiocarcinoma) patients. Based on a median survival of 1-year, <xref ref-type="other" rid="bib14">Schmidinger <italic>et al</italic> (2001)</xref> concluded that PLD warranted further studies. However, <xref ref-type="other" rid="bib13">Ruff <italic>et al</italic> (2001)</xref> who demonstrated a 17&#x00025; response rate achieved a median survival of only 5.3 months. The difficulty in relying on response rate as a marker of activity was further illustrated by <xref ref-type="other" rid="bib4">Hong and Tseng (2003)</xref>: despite 10&#x00025; of patients responding to treatment and a further 33&#x00025; achieving stable disease, the median survival was only 3 months.</p><p>A favourable toxicity profile has been consistent across all the HCC studies (<xref ref-type="other" rid="bib3">Halm <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib13">Ruff <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib14">Schmidinger <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib10">Miller <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib4">Hong and Tseng, 2003</xref>). We found few grade 3&#x02013;4 toxicities and notably none involving palmar-plantar erythrodysaesthesia, a dose-limiting toxicity seen in early studies along with stomatitis and neutropaenia (<xref ref-type="other" rid="bib11">Muggia <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib12">Ranson <italic>et al</italic>, 1997</xref>). Cardiac toxicity was not seen and dose reductions or dose delays due to toxicity were uncommon. Enhanced activity of PLD was postulated by increased leakage from capillaries in vascular tumours once the drug had evaded rapid hepatic uptake. This reduced uptake may, however, also be responsible for the lack of hepatotoxicity and, ultimately, efficacy.</p><p>Despite the ability to deliver doxorubicin more safely to patients, PLD has almost no activity in advanced HCC. This reflects the relative insensitivity of HCC to chemotherapy agents and success may come from alternative treatment modalities aimed at better targeting of the underlying pathological processes involved in HCC carcinogenesis.</p></sec></body><back><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>G</given-names></name><name><surname>Billingham</surname><given-names>M</given-names></name><name><surname>Alderman</surname><given-names>E</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Torti</surname><given-names>F</given-names></name><name><surname>Lum</surname><given-names>B</given-names></name><name><surname>Patek</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>FJ</given-names></name></person-group><article-title>The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin</article-title><source>Ann Oncol</source><year>1998</year><volume>9</volume><fpage>711</fpage><lpage>716</lpage><!--PubMed citation query: 'Ann Oncol||9|711||bib1|'--><pub-id pub-id-type="pmid">9739435</pub-id></citation></ref><ref id="bib2"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Engstrom</surname><given-names>PF</given-names></name><name><surname>Mc Glynn</surname><given-names>K</given-names></name><name><surname>Weese</surname><given-names>JL</given-names></name></person-group><article-title>Primary neoplasms of the liver</article-title><source>Cancer Medicine</source><year>1993</year><publisher-name>London: Lea and Febiger</publisher-name><fpage>1430</fpage><lpage>1441</lpage>Holland JF, Frei E (eds) pp</citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halm</surname><given-names>U</given-names></name><name><surname>Etzrodt</surname><given-names>G</given-names></name><name><surname>Schiefke</surname><given-names>I</given-names></name><name><surname>Schmidt</surname><given-names>F</given-names></name><name><surname>Witzigmann</surname><given-names>H</given-names></name><name><surname>Mossner</surname><given-names>J</given-names></name><name><surname>Berr</surname><given-names>F</given-names></name></person-group><article-title>A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma</article-title><source>Ann Oncol</source><year>2000</year><volume>11</volume><fpage>113</fpage><lpage>114</lpage><!--PubMed citation query: 'Ann Oncol||11|113||bib3|'--></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>RL</given-names></name><name><surname>Tseng</surname><given-names>YL</given-names></name></person-group><article-title>A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma</article-title><source>Cancer Chemother Pharmacol</source><year>2003</year><volume>51</volume><fpage>433</fpage><lpage>438</lpage><!--PubMed citation query: 'Cancer Chemother Pharmacol||51|433||bib4|'--><pub-id pub-id-type="pmid">12736762</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Wu</surname><given-names>PC</given-names></name><name><surname>Chan</surname><given-names>GC</given-names></name><name><surname>Lok</surname><given-names>AS</given-names></name><name><surname>Lin</surname><given-names>HJ</given-names></name></person-group><article-title>Doxorubicin <italic>versus</italic> no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial</article-title><source>Cancer</source><year>1988</year><volume>62</volume><fpage>479</fpage><lpage>483</lpage><!--PubMed citation query: 'Cancer||62|479||bib5|'--><pub-id pub-id-type="pmid">2839280</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival</article-title><source>Hepatology</source><year>2003</year><volume>37</volume><fpage>429</fpage><lpage>442</lpage><!--PubMed citation query: 'Hepatology||37|429||bib6|'--><pub-id pub-id-type="pmid">12540794</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Burroughs</surname><given-names>A</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Hepatocellular carcinoma</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>1907</fpage><lpage>1917</lpage><!--PubMed citation query: 'Lancet||362|1907||bib7|'--><pub-id pub-id-type="pmid">14667750</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Real</surname><given-names>MI</given-names></name><name><surname>Montana</surname><given-names>X</given-names></name><name><surname>Planas</surname><given-names>R</given-names></name><name><surname>Coll</surname><given-names>S</given-names></name><name><surname>Aponte</surname><given-names>J</given-names></name><name><surname>Ayuso</surname><given-names>C</given-names></name><name><surname>Sala</surname><given-names>M</given-names></name><name><surname>Muchart</surname></name><name><surname>Sola</surname><given-names>R</given-names></name><name><surname>Rodes</surname><given-names>J</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Arterial embolisation or chemoembolisation <italic>versus</italic> symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>1734</fpage><lpage>1739</lpage><!--PubMed citation query: 'Lancet||359|1734||bib8|'--><pub-id pub-id-type="pmid">12049862</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>CM</given-names></name><name><surname>Ngan</surname><given-names>H</given-names></name><name><surname>Tso</surname><given-names>WK</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Lam</surname><given-names>CM</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><name><surname>Fan</surname><given-names>ST</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name></person-group><article-title>Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma</article-title><source>Hepatology</source><year>2002</year><volume>35</volume><fpage>1164</fpage><lpage>1171</lpage><!--PubMed citation query: 'Hepatology||35|1164||bib9|'--><pub-id pub-id-type="pmid">11981766</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>RL</given-names></name><name><surname>Bowen</surname><given-names>KE</given-names></name><name><surname>Chun</surname><given-names>HG</given-names></name></person-group><article-title>A phase II study of liposomal doxorubicin (LD, Doxil) in patients with advanced hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC)</article-title><source>Proc Am Soc Clin Oncol</source><year>2002</year><volume>21</volume><fpage>(abstract 2324)</fpage><!--PubMed citation query: 'Proc Am Soc Clin Oncol||21|(abstract 2324)||bib10|'--></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muggia</surname><given-names>FM</given-names></name><name><surname>Hainsworth</surname><given-names>JD</given-names></name><name><surname>Jeffers</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>P</given-names></name><name><surname>Groshen</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><name><surname>Roman</surname><given-names>L</given-names></name><name><surname>Uziely</surname><given-names>B</given-names></name><name><surname>Muderspach</surname><given-names>L</given-names></name><name><surname>Garcia</surname><given-names>A</given-names></name><name><surname>Burnett</surname><given-names>A</given-names></name><name><surname>Greco</surname><given-names>FA</given-names></name><name><surname>Morrow</surname><given-names>CP</given-names></name><name><surname>Paradiso</surname><given-names>LJ</given-names></name><name><surname>Liang</surname><given-names>LJ</given-names></name></person-group><article-title>Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>987</fpage><lpage>993</lpage><!--PubMed citation query: 'J Clin Oncol||15|987||bib11|'--><pub-id pub-id-type="pmid">9060537</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ranson</surname><given-names>MR</given-names></name><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>O'Byrne</surname><given-names>K</given-names></name><name><surname>Stewart</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Howell</surname><given-names>A</given-names></name></person-group><article-title>Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>3185</fpage><lpage>3191</lpage><!--PubMed citation query: 'J Clin Oncol||15|3185||bib12|'--><pub-id pub-id-type="pmid">9336354</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruff</surname><given-names>P</given-names></name><name><surname>Moodley</surname><given-names>SD</given-names></name><name><surname>Rapoport</surname><given-names>DA</given-names></name><name><surname>Vorobiof</surname><given-names>DA</given-names></name><name><surname>Maart</surname><given-names>K</given-names></name><name><surname>Chasen</surname><given-names>MR</given-names></name></person-group><article-title>Long-term follow-up of pegylated liposomal doxorubicin (Caelyx): a well tolerated and effective agent in advanced hepatocellular carcinoma (HCC)</article-title><source>Proc Am Soc Clin Oncol</source><year>2001</year><volume>20</volume><fpage>(abstract 667)</fpage><!--PubMed citation query: 'Proc Am Soc Clin Oncol||20|(abstract 667)||bib13|'--></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidinger</surname><given-names>M</given-names></name><name><surname>Wenzel</surname><given-names>C</given-names></name><name><surname>Locker</surname><given-names>GJ</given-names></name><name><surname>Muehlbacher</surname><given-names>F</given-names></name><name><surname>Steininger</surname><given-names>R</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><name><surname>Crevenna</surname><given-names>R</given-names></name><name><surname>Budinsky</surname><given-names>AC</given-names></name></person-group><article-title>Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma</article-title><source>Br J Cancer</source><year>2001</year><volume>85</volume><fpage>1850</fpage><lpage>1852</lpage><!--PubMed citation query: 'Br J Cancer||85|1850||bib14|'--><pub-id pub-id-type="pmid">11747325</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Kumai</surname><given-names>K</given-names></name><name><surname>Uyama</surname><given-names>I</given-names></name><name><surname>Shibata</surname><given-names>S</given-names></name><name><surname>Tagawa</surname><given-names>T</given-names></name><name><surname>Nagaike</surname><given-names>K</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Kitajima</surname><given-names>M</given-names></name><name><surname>Tadakuma</surname><given-names>T</given-names></name></person-group><article-title>Improvement of pharmacokinetics and antitumor activity against human hepatoma cell line by using adriamycin-entrapped stealth liposomes</article-title><source>J Surg Oncol</source><year>1996</year><volume>62</volume><fpage>186</fpage><lpage>193</lpage><!--PubMed citation query: 'J Surg Oncol||62|186||bib15|'--><pub-id pub-id-type="pmid">8667626</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>R</given-names></name></person-group><article-title>Optimal two-stage designs for phase II clinical trials</article-title><source>Control Clin Trials</source><year>1989</year><volume>10</volume><fpage>1</fpage><lpage>10</lpage><!--PubMed citation query: 'Control Clin Trials||10|1||bib16|'--><pub-id pub-id-type="pmid">2702835</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uziely</surname><given-names>B</given-names></name><name><surname>Jeffers</surname><given-names>S</given-names></name><name><surname>Isacson</surname><given-names>R</given-names></name><name><surname>Kutsch</surname><given-names>K</given-names></name><name><surname>Wei-Tsao</surname><given-names>D</given-names></name><name><surname>Yehoshua</surname><given-names>Z</given-names></name><name><surname>Libson</surname><given-names>E</given-names></name><name><surname>Muggia</surname><given-names>FM</given-names></name><name><surname>Gabizon</surname><given-names>A</given-names></name></person-group><article-title>Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>1777</fpage><lpage>1785</lpage><!--PubMed citation query: 'J Clin Oncol||13|1777||bib17|'--><pub-id pub-id-type="pmid">7602367</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>JN</given-names></name></person-group><article-title>Liposomes as drug carriers in cancer therapy</article-title><source>Cancer Treat Rep</source><year>1984</year><volume>68</volume><fpage>127</fpage><lpage>135</lpage><!--PubMed citation query: 'Cancer Treat Rep||68|127||bib18|'--><pub-id pub-id-type="pmid">6692424</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>NZ</given-names></name><name><surname>Da</surname><given-names>D</given-names></name><name><surname>Rudoll</surname><given-names>TL</given-names></name><name><surname>Needham</surname><given-names>D</given-names></name><name><surname>Whorton</surname><given-names>AR</given-names></name><name><surname>Dewhirst</surname><given-names>MW</given-names></name></person-group><article-title>Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue</article-title><source>Cancer Res</source><year>1993</year><volume>53</volume><fpage>3765</fpage><lpage>3770</lpage><!--PubMed citation query: 'Cancer Res||53|3765||bib19|'--><pub-id pub-id-type="pmid">8339289</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Patient demographics</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Characteristics</bold></th><th align="center" valign="top" charoff="50"><bold>Number (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Patients entered</td><td align="center" valign="top" charoff="50">16</td></tr><tr><td align="left" valign="top" charoff="50">Age (years)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (range)</td><td align="center" valign="top" charoff="50">56 (23&#x02013;65)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Sex</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="center" valign="top" charoff="50">12 (75&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="center" valign="top" charoff="50">4 (25&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Performance status at enrolment (WHO)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="center" valign="top" charoff="50">3 (19&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="center" valign="top" charoff="50">13 (81&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Tumour histology</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Hepatocellular carcinoma</td><td align="center" valign="top" charoff="50">13 (81&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Fibrolamellar type</td><td align="center" valign="top" charoff="50">3 (19&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Tumour stage</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4A</td><td align="center" valign="top" charoff="50">7 (44&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4B</td><td align="center" valign="top" charoff="50">9 (56&#x00025;)</td></tr></tbody></table></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Reported toxicity by patient (<italic>n</italic>=16) and by cycle (<italic>n</italic>=47)</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="4" align="center" valign="top" char="." charoff="50"><bold>By patient</bold><hr/></th><th colspan="4" align="center" valign="top" char="." charoff="50"><bold>By cycle</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Toxicity/grade</bold></th><th align="char" valign="top" char="." charoff="50"><bold>1</bold></th><th align="char" valign="top" char="." charoff="50"><bold>2</bold></th><th align="char" valign="top" char="." charoff="50"><bold>3</bold></th><th align="char" valign="top" char="." charoff="50"><bold>4</bold></th><th align="char" valign="top" char="." charoff="50"><bold>1</bold></th><th align="char" valign="top" char="." charoff="50"><bold>2</bold></th><th align="char" valign="top" char="." charoff="50"><bold>3</bold></th><th align="char" valign="top" char="." charoff="50"><bold>4</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Haemoglobin</td><td align="char" valign="top" char="." charoff="50">63</td><td align="char" valign="top" char="." charoff="50">13</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">47</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">WBC</td><td align="char" valign="top" char="." charoff="50">13</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">13</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">Neutrophils</td><td align="char" valign="top" char="." charoff="50">13</td><td align="char" valign="top" char="." charoff="50">13</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">15</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">Platelets</td><td align="char" valign="top" char="." charoff="50">25</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">17</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Nausea/vomiting</td><td align="char" valign="top" char="." charoff="50">63</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">45</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Hepatic</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Bilirubin</td><td align="char" valign="top" char="." charoff="50">36</td><td align="char" valign="top" char="." charoff="50">27</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">26</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Alkaline phosphatase</td><td align="char" valign="top" char="." charoff="50">27</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">32</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;AST</td><td align="char" valign="top" char="." charoff="50">55</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">29</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Diarrhoea</td><td align="char" valign="top" char="." charoff="50">38</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">19</td><td align="char" valign="top" char="." charoff="50">15</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Lethargy</td><td align="char" valign="top" char="." charoff="50">31</td><td align="char" valign="top" char="." charoff="50">31</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">34</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Cutaneous</td><td align="char" valign="top" char="." charoff="50">25</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">28</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Anorexia</td><td align="char" valign="top" char="." charoff="50">19</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">11</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Fever/sepsis</td><td align="char" valign="top" char="." charoff="50">13</td><td align="char" valign="top" char="." charoff="50">13</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Mucositis</td><td align="char" valign="top" char="." charoff="50">13</td><td align="char" valign="top" char="." charoff="50">13</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Alopecia</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Constipation</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Cardiac</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr></tbody></table></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Contemporary studies of PLD in advanced HCC</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="left"/><col align="char" char="."/><col align="left"/><col align="char" char="."/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Study</bold></th><th align="char" valign="top" char="." charoff="50"><bold><italic>N</italic></bold></th><th align="left" valign="top" charoff="50"><bold>Dose</bold></th><th align="char" valign="top" char="." charoff="50"><bold>RR (&#x00025;)</bold></th><th align="left" valign="top" charoff="50"><bold>s.d. (&#x00025;)</bold></th><th align="char" valign="top" char="." charoff="50"><bold>MS (months)</bold></th><th align="left" valign="top" charoff="50"><bold>Reference</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Halm <italic>et al</italic> (2000)</td><td align="char" valign="top" char="." charoff="50">16</td><td align="left" valign="top" charoff="50">30&#x02013;40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> q3wks</td><td align="char" valign="top" char="." charoff="50">0</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">4.6</td><td align="left" valign="top" charoff="50">Halm <italic>et al</italic> (2000)</td></tr><tr><td align="left" valign="top" charoff="50">Miller <italic>et al</italic> (2002)</td><td align="char" valign="top" char="." charoff="50">10</td><td align="left" valign="top" charoff="50">50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> q4wks</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">30</td><td align="char" valign="top" char="." charoff="50">5.0</td><td align="left" valign="top" charoff="50">Miller <italic>et al</italic> (2002)</td></tr><tr><td align="left" valign="top" charoff="50">Valle <italic>et al</italic> (current study)</td><td align="char" valign="top" char="." charoff="50">16</td><td align="left" valign="top" charoff="50">50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> q4wks</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">19</td><td align="char" valign="top" char="." charoff="50">6.5</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Schmidinger <italic>et al</italic> (2001)</td><td align="char" valign="top" char="." charoff="50">17</td><td align="left" valign="top" charoff="50">40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> q4wks</td><td align="char" valign="top" char="." charoff="50">14</td><td align="char" valign="top" char="." charoff="50">36</td><td align="char" valign="top" char="." charoff="50">12</td><td align="left" valign="top" charoff="50">Schmidinger <italic>et al</italic> (2001)</td></tr><tr><td align="left" valign="top" charoff="50">Ruff <italic>et al</italic> (2001)</td><td align="char" valign="top" char="." charoff="50">42</td><td align="left" valign="top" charoff="50">50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> q4wks</td><td align="char" valign="top" char="." charoff="50">17</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">5.3</td><td align="left" valign="top" charoff="50">Ruff <italic>et al</italic> (2001)</td></tr><tr><td align="left" valign="top" charoff="50">Hong <italic>et al</italic> (2003)</td><td align="char" valign="top" char="." charoff="50">40</td><td align="left" valign="top" charoff="50">30&#x02013;45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> q3wks</td><td align="char" valign="top" char="." charoff="50">10</td><td align="char" valign="top" char="." charoff="50">33</td><td align="char" valign="top" char="." charoff="50">3</td><td align="left" valign="top" charoff="50">Hong and Tseng (2003)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>PLD=pegylated liposomal doxorubicin; HCC=hepatocellular carcinoma.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>


